Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1992 1
1993 2
1994 2
1995 2
1996 3
1997 2
1998 3
1999 2
2000 5
2002 2
2003 5
2004 3
2005 5
2006 5
2007 9
2008 7
2009 6
2010 9
2011 10
2012 5
2013 6
2014 6
2015 4
2016 8
2017 5
2018 3
2019 8
2020 7
2021 4
2022 7
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Results by year

Filters applied: . Clear all
Page 1
In skeletal muscle and neural crest cells, SMCHD1 regulates biological pathways relevant for Bosma syndrome and facioscapulohumeral dystrophy phenotype.
Laberthonnière C, Delourme M, Chevalier R, Dion C, Ganne B, Hirst D, Caron L, Perrin P, Adélaïde J, Chaffanet M, Xue S, Nguyen K, Reversade B, Déjardin J, Baudot A, Robin JD, Magdinier F. Laberthonnière C, et al. Among authors: chaffanet m. Nucleic Acids Res. 2023 Aug 11;51(14):7269-7287. doi: 10.1093/nar/gkad523. Nucleic Acids Res. 2023. PMID: 37334829 Free PMC article.
BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib.
Velazquez C, Orhan E, Tabet I, Fenou L, Orsetti B, Adélaïde J, Guille A, Thézénas S, Crapez E, Colombo PE, Chaffanet M, Birnbaum D, Sardet C, Jacot W, Theillet C. Velazquez C, et al. Among authors: chaffanet m. Front Oncol. 2023 Mar 17;13:1125021. doi: 10.3389/fonc.2023.1125021. eCollection 2023. Front Oncol. 2023. PMID: 37007122 Free PMC article.
Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial.
Sabatier R, Garnier S, Guille A, Carbuccia N, Pakradouni J, Adelaide J, Provansal M, Cappiello M, Rousseau F, Chaffanet M, Birnbaum D, Mamessier E, Gonçalves A, Bertucci F. Sabatier R, et al. Among authors: chaffanet m. Front Oncol. 2022 Jul 29;12:946257. doi: 10.3389/fonc.2022.946257. eCollection 2022. Front Oncol. 2022. PMID: 35965534 Free PMC article.
TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT.
de Nonneville A, Salas S, Bertucci F, Sobinoff AP, Adélaïde J, Guille A, Finetti P, Noble JR, Churikov D, Chaffanet M, Lavit E, Pickett HA, Bouvier C, Birnbaum D, Reddel RR, Géli V. de Nonneville A, et al. Among authors: chaffanet m. EMBO Mol Med. 2022 Oct 10;14(10):e15859. doi: 10.15252/emmm.202215859. Epub 2022 Aug 3. EMBO Mol Med. 2022. PMID: 35920001 Free PMC article.
Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy.
Neron M, Guille A, Allegre L, Colombo PE, Leaha C, Adelaide J, Carbuccia N, Courtier F, Boissiere F, Crapez E, Fabbro M, Gouy S, Mamessier E, Lambaudie É, Birnbaum D, Bertucci F, Chaffanet M. Neron M, et al. Among authors: chaffanet m. J Pers Med. 2022 Apr 19;12(5):655. doi: 10.3390/jpm12050655. J Pers Med. 2022. PMID: 35629078 Free PMC article.
Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial.
Billon E, Gravis G, Guille A, Carbuccia N, Adelaide J, Garnier S, Finetti P, Denicolaï E, Sfumato P, Brunelle S, Thomassin-Piana J, Pignot G, Walz J, Chabannon C, Pakradouni J, Sabatier R, Vicier C, Popovici C, Mamessier E, Gonçalves A, Birnbaum D, Chaffanet M, Bertucci F. Billon E, et al. Among authors: chaffanet m. Cancers (Basel). 2022 May 3;14(9):2275. doi: 10.3390/cancers14092275. Cancers (Basel). 2022. PMID: 35565404 Free PMC article.
Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate.
Cabaud O, Berger L, Crompot E, Adélaide J, Finetti P, Garnier S, Guille A, Carbuccia N, Farina A, Agavnian E, Chaffanet M, Gonçalves A, Charafe-Jauffret E, Mamessier E, Birnbaum D, Bertucci F, Lopez M. Cabaud O, et al. Among authors: chaffanet m. Mol Cancer Ther. 2022 Jul 5;21(7):1227-1235. doi: 10.1158/1535-7163.MCT-22-0013. Mol Cancer Ther. 2022. PMID: 35534238
Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study.
Sabatier R, Vicier C, Garnier S, Guille A, Carbuccia N, Isambert N, Dalenc F, Robert M, Levy C, Pakradouni J, Adelaïde J, Chaffanet M, Sfumato P, Mamessier E, Bertucci F, Goncalves A. Sabatier R, et al. Among authors: chaffanet m. Mol Oncol. 2022 May;16(10):2057-2070. doi: 10.1002/1878-0261.13188. Epub 2022 Mar 30. Mol Oncol. 2022. PMID: 35122700 Free PMC article. Clinical Trial.
TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients.
Vicier C, Sfumato P, Isambert N, Dalenc F, Robert M, Levy C, Rezai K, Provansal M, Adélaïde J, Garnier S, Guille A, Carbuccia N, Popovici C, Charafe-Jauffret E, Chaffanet M, Birnbaum D, Pakradouni J, Bertucci F, Boher JM, Sabatier R, Gonçalves A. Vicier C, et al. Among authors: chaffanet m. Eur J Cancer. 2021 Dec;159:205-214. doi: 10.1016/j.ejca.2021.09.040. Epub 2021 Nov 12. Eur J Cancer. 2021. PMID: 34781168 Clinical Trial.
132 results